Cell Biology of Endosomal Escape
- Institution
- BOSTON CHILDREN'S HOSPITAL, MA
- Principal investigator
- Tomas Kirchhausen
- Funding
- $463K
- Duration
- 2019–2029
Moonbase score
Still being scored
Abstract
How do large molecules, including biological therapeutics, reach the cytosol if delivered from outside the cell? Endocytic internalization (e.g., by clathrin-mediated endocytosis or fluid-phase uptake) is the principal route for bringing these molecules into cells, but most internalized cargo remains entrapped until degraded in lysosomes. Establishing potential mechanisms of endosome escape has generated long-standing controversy, largely because of technical limitations that prevent direct detection. Using recently developed 3D imaging modalities, especially lattice light-sheet microscopy (LLSM) and its combination with adaptive optics (AO-LLSM), we have shown that we can observe endosomal damage and repair and link it to events such as endosomal fission and cargo delivery. We will characterize the mechanism(s) of the delivery events and seek ways to regulate the delivery route, with the aim of achieving a full description of how endosomal membrane damage and repair govern endosomal escape. We will develop novel ways to exploit the deep-learning approaches that will be essential for analyzing the huge data sets we now generate (e.g., 3D, diffraction-limited movies of an entire cell in two or three colors at 2 sec intervals for 5 or more minutes). Our long-term goal is to build on mechanistic understanding to work out how to enhance specific release of desired cargo, such as antisense oligonucleotides (ASOs), microRNAs (miRNAs), and small interfering RNAs (siRNAs), or in other circumstances, how to prevent release of deleterious cargo, such as 𝛂-synuclein and lipopolysaccharide (LPS).
LOADING MOONBASE SCORE
Questions for BOSTON CHILDREN'S HOSPITAL
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same institution, same topic, scored first.
- NIH · Boston Children'S Hospital67
A 90 day, Phase 3, Open Labeled Exploratory Study of RELiZORB to Evaluate Safety, Tolerability, and Nutrient Absorption in Children with Short Bowel Syndrome who are Dependent on Parenteral Nutrition
Mark Puder · $365K · 2021–2028
- NIH · Boston Children'S Hospital64
Motion and Distortion Robust Diffusion Weighted Imaging Sequences for Pediatric Patients
Onur Afacan · $398K · 2022–2027
- NIH · Boston Children'S Hospital51
Insulin Regulation of Hepatic Function via Zone-Specific Transcriptional Programs
Sudha B Biddinger · $500K · 2021–2027